Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Jun 26, 2026 · Filed Jun 30, 2026
Vertex Pharmaceuticals's and CMO sold $288K of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$287,570
Shares × reported transaction price
53 days after results of May 4, 2026, 38 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $491.34 on Jun 26, 2026, within 2% of its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $499.17 (Mar 10, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $453.06 on May 13, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.1% | -0.1% | +0.1% |
| 30 days | -4.2% | +0.2% | -4.4% |
| 90 days | +5.8% | +2.5% | +3.3% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
2 different filers disclosed VRTX within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
